enGene (ENGN) and The Competition Financial Analysis

enGene (NASDAQ:ENGN) is one of 444 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare enGene to similar companies based on the strength of its earnings, analyst recommendations, institutional ownership, dividends, risk, profitability and valuation.

Profitability

This table compares enGene and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-63.25%	-5.65%
enGene Competitors	-11,728.20%	-125.44%	-24.26%

Volatility and Risk

enGene has a beta of -0.63, indicating that its stock price is 163% less volatile than the S&P 500. Comparatively, enGene’s peers have a beta of 1.23, indicating that their average stock price is 23% more volatile than the S&P 500.

Institutional & Insider Ownership

64.2% of enGene shares are held by institutional investors. Comparatively, 30.8% of shares of all “Biotechnology” companies are held by institutional investors. 13.7% of enGene shares are held by insiders. Comparatively, 22.5% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for enGene and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	0	0	6	0	3.00
enGene Competitors	749	2428	5726	67	2.57

enGene presently has a consensus price target of $34.40, indicating a potential upside of 464.86%. As a group, “Biotechnology” companies have a potential upside of 22.33%. Given enGene’s stronger consensus rating and higher possible upside, equities research analysts plainly believe enGene is more favorable than its peers.

Valuation and Earnings

This table compares enGene and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
enGene	N/A	$104.74 million	-3.74
enGene Competitors	$156.34 million	-$18.62 million	-72.16

enGene’s peers have higher revenue, but lower earnings than enGene. enGene is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Dividends

enGene pays an annual dividend of $1.58 per share and has a dividend yield of 26.0%. enGene pays out -97.0% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 3.1% and pay out 5,072.0% of their earnings in the form of a dividend. enGene is clearly a better dividend stock than its peers, given its higher yield and lower payout ratio.

Summary

enGene beats its peers on 11 of the 15 factors compared.

enGene Company Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.